Cardiogenic shock risk factors: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 14: | Line 14: | ||
*[[Peripheral vascular disease]]<ref name="pmid8452150">{{cite journal| author=Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S| title=Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. | journal=Am J Med | year= 1993 | volume= 94 | issue= 3 | pages= 265-73 | pmid=8452150 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8452150 }} </ref> | *[[Peripheral vascular disease]]<ref name="pmid8452150">{{cite journal| author=Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S| title=Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. | journal=Am J Med | year= 1993 | volume= 94 | issue= 3 | pages= 265-73 | pmid=8452150 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8452150 }} </ref> | ||
*[[Left ventricular ejection fraction]] < 35%<ref name="HandsRutherford1989">{{cite journal|last1=Hands|first1=Mark E.|last2=Rutherford|first2=John D.|last3=Muller|first3=James E.|last4=Davies|first4=Glenn|last5=Stone|first5=Peter H.|last6=Parker|first6=Corette|last7=Braunwald|first7=Eugene|title=The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors|journal=Journal of the American College of Cardiology|volume=14|issue=1|year=1989|pages=40–46|issn=07351097|doi=10.1016/0735-1097(89)90051-X}}</ref> | *[[Left ventricular ejection fraction]] < 35%<ref name="HandsRutherford1989">{{cite journal|last1=Hands|first1=Mark E.|last2=Rutherford|first2=John D.|last3=Muller|first3=James E.|last4=Davies|first4=Glenn|last5=Stone|first5=Peter H.|last6=Parker|first6=Corette|last7=Braunwald|first7=Eugene|title=The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors|journal=Journal of the American College of Cardiology|volume=14|issue=1|year=1989|pages=40–46|issn=07351097|doi=10.1016/0735-1097(89)90051-X}}</ref> | ||
*[[Diabetes mellitus]]<ref name="HandsRutherford1989">{{cite journal|last1=Hands|first1=Mark E.|last2=Rutherford|first2=John D.|last3=Muller|first3=James E.|last4=Davies|first4=Glenn|last5=Stone|first5=Peter H.|last6=Parker|first6=Corette|last7=Braunwald|first7=Eugene|title=The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors|journal=Journal of the American College of Cardiology|volume=14|issue=1|year=1989|pages=40–46|issn=07351097|doi=10.1016/0735-1097(89)90051-X}}</ref> | *[[Diabetes mellitus]]<ref name="HandsRutherford1989">{{cite journal|last1=Hands|first1=Mark E.|last2=Rutherford|first2=John D.|last3=Muller|first3=James E.|last4=Davies|first4=Glenn|last5=Stone|first5=Peter H.|last6=Parker|first6=Corette|last7=Braunwald|first7=Eugene|title=The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors|journal=Journal of the American College of Cardiology|volume=14|issue=1|year=1989|pages=40–46|issn=07351097|doi=10.1016/0735-1097(89)90051-X}}</ref> | ||
*Larger [[infarct]] area (estimated by serial cardiac markers)<ref name="HandsRutherford1989">{{cite journal|last1=Hands|first1=Mark E.|last2=Rutherford|first2=John D.|last3=Muller|first3=James E.|last4=Davies|first4=Glenn|last5=Stone|first5=Peter H.|last6=Parker|first6=Corette|last7=Braunwald|first7=Eugene|title=The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors|journal=Journal of the American College of Cardiology|volume=14|issue=1|year=1989|pages=40–46|issn=07351097|doi=10.1016/0735-1097(89)90051-X}}</ref> | *Larger [[infarct]] area (estimated by serial cardiac markers)<ref name="HandsRutherford1989">{{cite journal|last1=Hands|first1=Mark E.|last2=Rutherford|first2=John D.|last3=Muller|first3=James E.|last4=Davies|first4=Glenn|last5=Stone|first5=Peter H.|last6=Parker|first6=Corette|last7=Braunwald|first7=Eugene|title=The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors|journal=Journal of the American College of Cardiology|volume=14|issue=1|year=1989|pages=40–46|issn=07351097|doi=10.1016/0735-1097(89)90051-X}}</ref> | ||
*3 vessel disease | *3 vessel disease | ||
*Early use of [[beta blockers]] in large infarcts | *Early use of [[beta blockers]] in large infarcts | ||
| Line 22: | Line 21: | ||
*Sinus tachycardia > 110 bpm | *Sinus tachycardia > 110 bpm | ||
*Heart rate < 60 bpm<ref>{{Cite journal | last1 = Antman | first1 = EM. | last2 = Hand | first2 = M. | last3 = Armstrong | first3 = PW. | last4 = Bates | first4 = ER. | last5 = Green | first5 = LA. | last6 = Halasyamani | first6 = LK. | last7 = Hochman | first7 = JS. | last8 = Krumholz | first8 = HM. | last9 = Lamas | first9 = GA. | title = 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal = J Am Coll Cardiol | volume = 51 | issue = 2 | pages = 210-47 | month = Jan | year = 2008 | doi = 10.1016/j.jacc.2007.10.001 | PMID = 18191746 }}</ref> | *Heart rate < 60 bpm<ref>{{Cite journal | last1 = Antman | first1 = EM. | last2 = Hand | first2 = M. | last3 = Armstrong | first3 = PW. | last4 = Bates | first4 = ER. | last5 = Green | first5 = LA. | last6 = Halasyamani | first6 = LK. | last7 = Hochman | first7 = JS. | last8 = Krumholz | first8 = HM. | last9 = Lamas | first9 = GA. | title = 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal = J Am Coll Cardiol | volume = 51 | issue = 2 | pages = 210-47 | month = Jan | year = 2008 | doi = 10.1016/j.jacc.2007.10.001 | PMID = 18191746 }}</ref> | ||
*According to the analysis of PURSUIT trial database<ref name="pmid10987585">{{cite journal| author=Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW et al.| title=Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 3 | pages= 685-92 | pmid=10987585 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10987585 }} </ref> in [[non-ST segment elevation myocardial infarction]] patients who received eptificatide saw their 30-day mortality risk reduced by 50%. | |||
==References== | ==References== | ||
Revision as of 23:30, 30 April 2014
|
Cardiogenic Shock Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiogenic shock risk factors On the Web |
|
American Roentgen Ray Society Images of Cardiogenic shock risk factors |
|
Risk calculators and risk factors for Cardiogenic shock risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
The identification of high-risk groups for developing cardiogenic shock, particularly in ACS patients (since this is the most common cause of this type of shock), and its promoting factors is mandatory for the improvement of the survival rate of these patients by providing adequate therapeutic measures and avoiding others which might otherwise lead to iatrogenic shock.[1]
Risk Factors
According to several studies there are risk factors which are associated with the development of cardiogenic shock. These include:
- Female sex[2]
- Older age (> 65 years)[3] For every 10 years of age, the risk is 47% greater.[4]
- Prior myocardial infarction (MI)[2]
- Prior angina[2]
- Peripheral vascular disease[2]
- Left ventricular ejection fraction < 35%[3]
- Diabetes mellitus[3]
- Larger infarct area (estimated by serial cardiac markers)[3]
- 3 vessel disease
- Early use of beta blockers in large infarcts
- Systolic blood pressure < 120 mm Hg
- Sinus tachycardia > 110 bpm
- Heart rate < 60 bpm[5]
- According to the analysis of PURSUIT trial database[6] in non-ST segment elevation myocardial infarction patients who received eptificatide saw their 30-day mortality risk reduced by 50%.
References
- ↑ Hasdai, David. (2002). Cardiogenic shock : diagnosis and treatmen. Totowa, N.J.: Humana Press. ISBN 1-58829-025-5.
- ↑ 2.0 2.1 2.2 2.3 Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S (1993). "Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group". Am J Med. 94 (3): 265–73. PMID 8452150.
- ↑ 3.0 3.1 3.2 3.3 Hands, Mark E.; Rutherford, John D.; Muller, James E.; Davies, Glenn; Stone, Peter H.; Parker, Corette; Braunwald, Eugene (1989). "The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors". Journal of the American College of Cardiology. 14 (1): 40–46. doi:10.1016/0735-1097(89)90051-X. ISSN 0735-1097.
- ↑ Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M; et al. (2000). "Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction". J Am Coll Cardiol. 35 (1): 136–43. PMID 10636271.
- ↑ Antman, EM.; Hand, M.; Armstrong, PW.; Bates, ER.; Green, LA.; Halasyamani, LK.; Hochman, JS.; Krumholz, HM.; Lamas, GA. (2008). "2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 51 (2): 210–47. doi:10.1016/j.jacc.2007.10.001. PMID 18191746. Unknown parameter
|month=ignored (help) - ↑ Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW; et al. (2000). "Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation". J Am Coll Cardiol. 36 (3): 685–92. PMID 10987585.